This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2006 by New York State Psychiatric Institute.
Recruitment status was:  Active, not recruiting
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
New York State Psychiatric Institute Identifier:
First received: July 5, 2001
Last updated: November 1, 2013
Last verified: October 2006
This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).

Condition Intervention Phase
Attention Deficit Disorder With Hyperactivity Drug: Methylphenidate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Methylphenidate Efficacy and Safety in ADHD Preschoolers

Resource links provided by NLM:

Further study details as provided by New York State Psychiatric Institute:

Estimated Enrollment: 165
Study Start Date: April 2001
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Detailed Description:
Young children age 3-5.5 years will be studied. The study includes treatment with different doses of methylphenidate and placebo; all children will receive active medication during the study. Prior to treatment, each child will receive a thorough psychiatric evaluation and each guardian will complete a 10-week workshop (2 hours/week). Throughout the study, parents and teachers will complete forms that report on the child's behavior and possible side effects. Participants will be monitored by regular visits with a study physician. Most participants will be involved in the study for up to 16 months to ensure optimal evaluation, dosing, and monitoring

Ages Eligible for Study:   3 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Boys and girls who are:

  • Between the ages of 3-5.5 years
  • Qualified as having ADHD by our diagnostic evaluations and clinical staff
  • Otherwise generally healthy
  • Willing, and have parents that are willing, to attend all visits required by the study
  • Enrolled in some type of day-program: day care, preschool, nursery school, kindergarten, for at least 2 half days/week
  • In classrooms with teachers that are willing to participate by completing rating scale
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00018863

United States, California
University of California, Irvine
Irvine, California, United States
University of California, Los Angeles
Los Angeles, California, United States
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States
United States, New York
New York State Psychiatric Institute
New York, New York, United States
New York University School of Medicine
New York, New York, United States
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)
Study Chair: Laurence Greenhill, M.D.
  More Information

Additional Information:
Conners CK: Controlled trial of methylphenidate in preschool children with minimal brain dysfunction. Int J Ment Health (4):61-74, 1975.

Responsible Party: New York State Psychiatric Institute Identifier: NCT00018863     History of Changes
Other Study ID Numbers: #3761
U01MH060903 ( U.S. NIH Grant/Contract )
U01MH060642 ( U.S. NIH Grant/Contract )
U01MH060943 ( U.S. NIH Grant/Contract )
U01MH060848 ( U.S. NIH Grant/Contract )
U01MH060900 ( U.S. NIH Grant/Contract )
U01MH060833 ( U.S. NIH Grant/Contract )
Study First Received: July 5, 2001
Last Updated: November 1, 2013

Keywords provided by New York State Psychiatric Institute:

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents processed this record on July 19, 2017